ASH 2024 | Clinical outcomes of patients with R/R B-cell ALL receiving CAR-T
Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, comments on the findings of a systematic review and meta-analysis of clinical trials of patients treated with second-generation autologous CAR T-cell therapies for B-cell acute lymphoblastic leukemia (ALL). Dr Barba notes that the majority of patients achieved complete remissions, with most being MRD-negative, and that constructs using 4-1BB as costimulatory domain showed better safety profiles and efficacy compared to those using CD28. Additionally, trials involving pediatric patients reported better outcomes compared to those in adults, highlighting the importance of considering trial populations when comparing results. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
